Hannah Pollard
Overview
Explore the profile of Hannah Pollard including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
201
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hoskins K, Montgomery M, Griffith A, Pollard H, Orr-Roderick D, Schmick D, et al.
J Osteopath Med
. 2025 Feb;
PMID: 39946209
Context: Following the transition to a single graduate medical education (GME) accreditation system in 2020, leaders at American Association of Colleges of Osteopathic Medicine (AACOM) were interested in learning more...
2.
Srinivasan M, Pollard H, Chapman D, Tonga K, Patel K, Blokland K, et al.
ERJ Open Res
. 2024 Nov;
10(6).
PMID: 39588072
Introduction: COPD is characterised by airflow obstruction, expiratory airway collapse and closure causing expiratory flow limitation (EFL) and hyperinflation. Supine posture may worsen ventilatory function in COPD, which may cause...
3.
Barlaam B, Boiko S, Boyd S, Dry H, Gingipalli L, Ikeda T, et al.
Bioorg Med Chem Lett
. 2020 Sep;
30(22):127523.
PMID: 32877741
Hybridisation of amino-pyrimidine based SYK inhibitors (e.g. 1a) with previously reported diamine-based SYK inhibitors (e.g. TAK-659) led to the identification and optimisation of a novel pyrimidine-based series of potent and...
4.
Kawatkar S, Barlaam B, Kemmitt P, Simpson I, Watson D, Wang P, et al.
Bioorg Med Chem Lett
. 2020 Jul;
30(18):127393.
PMID: 32721854
Spleen Tyrosine Kinase (SYK) is a well-studied enzyme with therapeutic applications in oncology and autoimmune diseases. We identified an azabenzimidazole (ABI) series of SYK inhibitors by mining activity data of...
5.
Baretic D, De Oliveira T, Niess M, Wan P, Pollard H, Johnson C, et al.
Prog Biophys Mol Biol
. 2019 Jul;
147:4-16.
PMID: 31255703
ATM, ATR and DNA-PKCs are key effectors of DNA Damage response and have been extensively linked to tumourigenesis and survival of cancer cells after radio/chemotherapy. Despite numerous efforts, the structures...
6.
Dowling J, Chuaqui C, Pontz T, Lyne P, Larsen N, Block M, et al.
ACS Med Chem Lett
. 2014 Jun;
3(4):278-83.
PMID: 24900464
In this paper we describe a series of 3-cyano-5-aryl-7-aminopyrazolo[1,5-a]pyrimidine hits identified by kinase-focused subset screening as starting points for the structure-based design of conformationally constrained 6-acetamido-indole inhibitors of CK2. The...
7.
Dakin L, Block M, Chen H, Code E, Dowling J, Feng X, et al.
Bioorg Med Chem Lett
. 2012 Jun;
22(14):4599-604.
PMID: 22727640
Novel substituted benzylidene-1,3-thiazolidine-2,4-diones (TZDs) have been identified as potent and highly selective inhibitors of the PIM kinases. The synthesis and SAR of these compounds are described, along with X-ray crystallographic,...
8.
Ferguson A, Larsen N, Howard T, Pollard H, Green I, Grande C, et al.
Structure
. 2011 Jul;
19(9):1262-73.
PMID: 21782458
Protein lysine methyltransferases are important regulators of epigenetic signaling. These enzymes catalyze the transfer of donor methyl groups from S-adenosylmethionine to specific acceptor lysines on histones, leading to changes in...
9.
Ioannidis S, Lamb M, Wang T, Almeida L, Block M, Davies A, et al.
J Med Chem
. 2010 Dec;
54(1):262-76.
PMID: 21138246
The myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis are a heterogeneous but related group of hematological malignancies characterized by clonal expansion of one or more myeloid lineages. The...